Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients

Human Immunology

Volumn 74, Issue 8, 2013, Pages 907-910

  Nisihara, Renato M ^a,b   Magrini, Fernanda ^a   Mocelin, Valmir ^a   Messias Reason, Iara J ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b POSITIVO UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; FICOLIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LECTIN; MANNAN BINDING LECTIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGEN-ANTIBODY COMPLEX; BIOPSY; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; KIDNEY; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; MICROSCOPY, FLUORESCENCE; YOUNG ADULT;

EID: 84879858237     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.030     Document Type: Article

References (26)

1. Borchers A.T., Leibushor N., Naguwa S.M., Cheema S.G., Shoenfeld M.Y., Gershwin E. Lupus nephritis: a critical review. Autoimmunity Rev 2012, 2:174-194.
2. Wenning, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
3. Lewis E.J., Schwartz M.M. Pathology of lupus nephritis. Lupus 2005, 14:31-38.
4. Fries J.W., Mendrick D.L., Rennke H.G. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988, 34:333-345.
5. Schwartz M.M. The pathology of lupus nephritis. Semin Nephrol 2007, 27:22-34.
6. Turner M.W. The role of mannose binding lectin in health and disease. Mol Immunol 2003, 40:423-429.
7. Messias Reason I.J., Schafranski M.D., Jensenius J.C., Steffensen R. The association between mannose-binding lectin gene polymorphism and rheumatic heart disease. Hum Immunol 2006, 67:991-998.
8. Schafranski M.D., Stier A., Nisihara R., Messias-Reason I.J.T. Significantly increased levels of mannose-binding lectin in rheumatic heart disease: a beneficial role for MBL deficiency. Clin Exp Immunol 2004, 138:521-525.
9. Takahashi R., Tsutsumi A., Ohtani K., Muraki Y., Goto D., Matsumoto I., et al. Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus. Ann Rheum Dis 2005, 64:311-314.
10. Runza V.L., Schwaeble W., Mannel D.N. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008, 213:297-306.
11. Watanabe H., Saito R., Asano T., Sato S., Iwadate H., Kobayashi H., et al. Serum L-ficolin levels in patients with systemic lupus erythematosus. Mod Rheumatol 2012, 22:899-902.
12. Sato N., Ohsawa I., Nagamachi S., et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 2011, 20:1378-1386.
13. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725-1737.
14. Markowitz G.S., D'Agati V.D. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3years. Kidney Int 2007, 71:491-495.
15. Mok C.C. Prognostic factors in lupus nephritis. Lupus 2005, 14:39-44.
16. Endo M., Ohi H., Ohsawa T.I., Fujita M.M., Fujita T. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998, 13:1984-1990.
17. Roos A., Rastaldi M.P., Calvaresi N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006, 17:1724-1734.
18. Riedemann N.C., Ward P.A. Complement in ischemia reperfusion injury. Am J Pathol 2003, 162:363-367.
19. Vielhauer V., Kulkarni O., Reichel C.A., Anders H.J. Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 2010, 30:318-333.
20. Messias-Reason I.J., Nisihara R.M., Mocelin V. Mannan-binding lectin and ficolin deposition in skin lesions of pemphigus. Arch Dermatol Res 2011, 303:521-525.
21. Rabinovich G.A., van Booyk Y., Cobb B.A. Glycobiology of immune responses. Ann NY Acad Sci 2012, 1253:1-15.
22. Chiu Y.Y., Nisihara R.M., Würzner R., Kirschfink M., Messias-Reason I.J. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998, 8:239-244.
23. Nangaku M., Couser W.G. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005, 9:183-191.
24. Cravedi P. Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art. G Ital Nefrol 2012, 29:274-282.
25. Rother R.P., Mojcik C.F. McCroskery EW Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004, 13:328-334.
26. Kattah A.G., Fervenza F.C. Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Rev Clin Immunol 2012, 8:413-421.